Perceptive Advisors MDGL Position
Exited10-Fund ConvergencePerceptive Advisors exited their position in Madrigal Pharmaceuticals Inc. (MDGL) in Q3 2024, after holding the stock for 7 quarters.
The position was first reported in Q1 2023 and has been tracked across 7 quarterly 13F filings.
MDGL is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Resmetirom in 259 days (Dec 31, 2026), making the timing of Perceptive's position particularly relevant.
Short interest stands at 19.8% of float with 10.6 days to cover, indicating significant bearish positioning against the stock.
About Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Full company profile →Short Interest
19.8%
10.6 days to cover
Perceptive Advisors MDGL Position History
Frequently Asked Questions
Does Perceptive Advisors own MDGL?
No. Perceptive Advisors exited their position in Madrigal Pharmaceuticals Inc. (MDGL) in Q3 2024. They previously held the stock for 7 quarters.
How many hedge funds own MDGL?
10 specialist biotech hedge funds currently hold MDGL, including Baker Bros. Advisors, RTW Investments, Avoro Capital Advisors and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy MDGL?
Perceptive Advisors's position in MDGL was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's MDGL position increasing or decreasing?
Perceptive Advisors completely exited their MDGL position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MDGLCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →